Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mbote-HIVAX: MVA-BN Vaccine for Mpox Prevention in Adults with HIV
NCT06839989Phase 2Active, not recruiting
- Sponsor
- Institute of Tropical Medicine Antwerp
- Start
- Aug 2025
- Primary completion
- May 2026
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of JYNNEOS in mpox (3 arms), sponsored by Institute of Tropical Medicine Antwerp. Primary endpoint: Seroconversion rates for monkeypox virus (MPXV) neutralizing antibodies at 6 weeks. Started Aug 2025; status: active, not recruiting.
02
Drugs
JYNNEOS
03
Conditions
mpox
Beyond the preview
Go deeper on NCT06839989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839989.